<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995783</url>
  </required_header>
  <id_info>
    <org_study_id>20201349</org_study_id>
    <secondary_id>2R44HG010445-02</secondary_id>
    <nct_id>NCT04995783</nct_id>
  </id_info>
  <brief_title>Predicting Medication Response for Autoimmune Disease</brief_title>
  <acronym>REEF</acronym>
  <official_title>Predicting Medication Response for Autoimmune Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coral Genomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Human Genome Research Institute (NHGRI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Coral Genomics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coral is conducting a large study comparing and predicting the relative effectiveness of&#xD;
      different medications for autoimmune patients.&#xD;
&#xD;
      Patients with Inflammatory Bowel Disease (IBD) who have been diagnosed with either Ulcerative&#xD;
      Colitis or Crohn's Disease and are undergoing treatment are eligible to participate.&#xD;
&#xD;
      Patients with Rheumatoid Arthritis (RA) and Psoriasis (Ps) will also be enrolled.&#xD;
&#xD;
      A novel clinical test will be performed to predict the responsiveness of a particular patient&#xD;
      to different immune modulating therapies used in these conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prediction of medication response</measure>
    <time_frame>retrospective and 6 months prospectively</time_frame>
    <description>AUC measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prediction of disease severity</measure>
    <time_frame>at enrollment</time_frame>
    <description>R-squared measure of predicting current disease severity measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Classification of disease</measure>
    <time_frame>at enrollment</time_frame>
    <description>AUC measure at determining the diagnosis/disease of a patient</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Crohn's Disease</condition>
  <condition>Psoriasis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Ulcerative Colitis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn's Disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Coral FRS test</intervention_name>
    <description>A novel clinical test to predict autoimmune medication response</description>
    <arm_group_label>Crohn's Disease</arm_group_label>
    <arm_group_label>Psoriasis</arm_group_label>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
    <arm_group_label>Ulcerative Colitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study population will include adults 18 years and older who have been diagnosed with one of&#xD;
        the four autoimmune conditions.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis, Psoriasis diagnosis&#xD;
&#xD;
          -  On or about to begin a treatment for condition above&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Atray Dixit, PhD</last_name>
    <phone>‪872-267-2549‬</phone>
    <email>atray@coralgenomics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Coral Genomics, Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atray Dixit</last_name>
      <phone>‪872-267-2549‬</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared in the NIH dbGAP repository</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

